miRNA Panel for Mcl-1 Silencing and Cancer Sensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying miRNA targets are unreliable, leading to a high number of false positives and false negatives, which complicates the evaluation of cancer cell sensitivity to Bcl-2 family protein inhibitors like ABT-263, particularly due to the low affinity of these inhibitors for Mcl-1.
Innovation Solution
A panel of oligonucleotide primers or probes is developed to determine miRNA profiles in biological samples, specifically targeting miRNAs that can sensitize cancer cells to Bcl-2 family protein inhibitors by down-regulating Mcl-1 expression, thereby increasing sensitivity to treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current target prediction tools are used to identify miRNA targets, then the identification process can be performed, but the results are unreliable with a large number of false positives and false negatives
Solution Approach 1:
The patent segments the miRNA target identification process into multiple validated stages: in silico prediction followed by experimental validation (luciferase reporter assays, Western blotting). This segmentation allows initial high-throughput screening while maintaining reliability through subsequent validation steps for each predicted target.
Solution Approach 2:
The patent implements feedback mechanisms where predicted miRNA targets are experimentally validated, and the results feed back into refining the prediction algorithms. The validated target information is used to improve future predictions, reducing false positives and false negatives in subsequent identifications.
2Reliability
If Bcl-2 family protein inhibitors like ABT-263 are used to treat cancer, then they can inhibit Bcl-2, Bcl-xl, and Bcl-w, but they have low affinity for Mcl-1 and thus cannot effectively treat tumors with high Mcl-1 expression
Solution Approach 1:
The patent uses miRNAs as intermediaries to indirectly reduce Mcl-1 protein levels. Instead of designing a drug that directly binds Mcl-1, the invention employs miRNAs that bind to Mcl-1 mRNA to suppress translation, thereby achieving Mcl-1 inhibition through a mediating molecular mechanism.
Solution Approach 2:
The patent changes the therapeutic parameter from direct protein binding affinity to gene expression regulation. By shifting from small molecule inhibitors (which rely on binding affinity) to miRNA-based therapy (which regulates translation), the treatment can effectively reduce Mcl-1 levels without requiring high affinity for the Mcl-1 protein.
3Adaptability or versatility
If multiple miRNA targets need to be evaluated, then comprehensive profiling is required, but current methods lack reliability leading to incorrect sensitivity evaluations
Solution Approach 1:
The patent segments the miRNA evaluation into specific functionally-validated miRNAs (miR-15a, miR-16-1, miR-29b, miR-125b, miR-193a, miR-320) rather than attempting to evaluate all miRNAs. This focused segmentation maintains comprehensive coverage of Mcl-1 regulating miRNAs while improving reliability through functional validation.
Solution Approach 2:
The patent changes the evaluation parameter from general miRNA expression levels to functionally-validated miRNA activity levels. By focusing on miRNAs with experimentally confirmed Mcl-1 targeting capability, the evaluation becomes more reliable while still maintaining versatility in assessing cancer cell sensitivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution effectively sensitizes cancer cells to Bcl-2 family protein inhibitors, promoting apoptosis by decreasing Mcl-1 protein levels, thereby overcoming resistance to treatments like ABT-263.
Implementation Method 1
a panel of oligonucleotide primers or probes for determining an miRNA profile in a biological sample, the panel comprising at least two miRNA primers or probes, each primer or probe capable of selectively binding one of at least two human miRNA
Implementation Method 2
MiRNAs are small non-coding RNAs that regulate global gene expression by binding to the 3′ UTRs of their target genes and repressing translation
Data Source
AI summary
MicroRNAs (miRNAs) that sensitize cancer cells to Bcl-2 family protein inhibitors are identified and described. Oligonucleotide panels, arrays and methods using the sensitizing miRNAs are also disclosed.